Clinical Trial Update: Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating adjuvant anti-mineralocorticoid-receptor treatment for anti-VEGF refractory neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Snippet

Sponsor: Dr Irmela MANTEL | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED